Matibenz 400 Tablets

Generic Name- Imatinib mesylate

Drug Class- Antineoplastic agent

Imatinib a tyrosine kinase inhibitor, which was initially approved for the treatment of chronic myeloid leukemia. Its use has now extended to various other cancers and has achieved first-line position in cancers like Ph+ ALL, advanced dermatofibrosarcoma protuberans (DFPS), hypereosinophilic syndrome (HS), and systemic mastocytosis (SM). It blocks constitutive action of protein tyrosine kinase by working as a competitive inhibitor of the ATP binding cleft of ABL inducing apoptosis of leukemic cells.



Matibenz 400 (Imatinib mesylate) is an oral anti-cancer drug, available in tablet form.